Positive Test Results and Acquisitions Drive Shares of Exelixis and Anadys Higher
26 10월 2011 - 9:16PM
Marketwired
Drug approvals from administrative bodies in both the U.S. and
Europe have been pivotal for biotech companies recently. Investors
have been particularly sensitive to decisions made on new drugs
considering the state of the global economic recovery. The Paragon
Report examines investing opportunities in the Biotechnology
Industry and provides equity research on Exelixis, Inc. (NASDAQ:
EXEL) and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS). Access to
the full company reports can be found at:
www.paragonreport.com/EXEL www.paragonreport.com/ANDS
While there are some success stories in the industry, a number
of players are having trouble dealing with the volatile nature of
biotechnologies. Research and development costs are extremely high,
and the success of a product can sometimes not be measured until
late in development. According to Krishan Maggon, a Geneva-based
pharmaceuticals consultant, the number of new biotech drugs
approved in the U.S. has remained in the 20 to 25 range during the
past four years, while in Europe the figure was a record-low 14
last year.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the biotechnology industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Earlier this week share of Exelixis skyrocketed after the
company said its most advanced experimental drug more than doubled
the amount of survival time of patients with a type of thyroid
cancer. Exelixis said it will meet the Food and Drug
Administration, and will ask if it can submit its application for
approval of cabozantinib piece-by-piece instead of waiting to file
its application all at once. The company plans to finish its
application in the first half of 2012. The FDA has agreed to
approve cabozantinib if data shows it improves patients'
survival.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company,
engages in developing novel medicines for the treatment of
hepatitis C in the United States. Shares of the company skyrocketed
this month after Swiss drugmaker Roche Holding AG announced that it
is paying $230 million to take over Anadys.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Anadys (NASDAQ:ANDS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Anadys (NASDAQ:ANDS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Anadys Pharmaceuticals (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Paragon Financial Limited News Articles